U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of the Commissioner
  5. Office of the Chief Scientist
  6. National Center for Toxicological Research
  7. Science & Research (NCTR)
  8. Suresh Nagumalli
  1. Science & Research (NCTR)

Suresh K. Nagumalli Ph.D.
Leadership Role

Visiting Scientist — Division of Biochemical Toxicology

Headshot of Dr. Suresh Nagumalli

Suresh K. Nagumalli, Ph.D.
(870) 543-7121
NCTRResearch@fda.hhs.gov  

Back to NCTR Principal Investigators page

About  |  Publications

Background

Dr. Suresh K. Nagumalli earned a Ph.D. in Pharmacy from the University of Louisiana at Monroe (ULM), where he focused on leveraging multivariate analytical techniques to identify the chemical constituents within Echinacea species responsible for their bioactivity. His doctoral research at ULM elucidated the pharmacological and toxicological properties of three Echinacea species, with the aim of enhancing understanding of these herbal medicines. Dr. Nagumalli employed statistical methods—such as Principal Component Analysis (PCA) and Orthogonal Partial Least Squares Discriminant Analysis—to establish a correlation between pharmacological activity and specific proton nuclear magnetic resonance (1H-NMR) regions. Additionally, he investigated the effects of Echinacea on clinical chemistry and hematological parameters to enhance understanding of Echinacea’s bioactive components and their toxicological profiles.

Dr. Nagumalli was inducted into The Honor Society of Phi Kappa Phi, America’s oldest and most selective multidisciplinary honor society. His research at ULM earned him a Burdock Group Travel Award from the Society of Toxicology (SOT). Dr. Nagumalli also received an Outstanding Graduate Student Leadership Award from SOT. He has co-authored six peer-reviewed research articles and one book chapter—serving as the first author on two, co-author on another two, and both first and corresponding author on the remaining two articles.

Research Interests

Dr. Nagumalli's research primarily focuses on developing in vitro methodologies to assess the suitability of animal models used in in vivo studies. This research involves utilizing S9 fractions and advanced ultra performance liquid chromatography-high resolution mass spectrometry analysis to refine the accuracy and quality of studies concerning the toxicity and pharmacological effects of test articles. Furthermore, Dr. Nagumalli is creating analytical chemistry methods to quantify small molecules in biological matrices. These methods have potential applications ranging from therapeutic uses to drug development, environmental surveillance, forensic investigations, and toxicity evaluations. In his role at NCTR, Dr. Nagumalli has emphasized the importance of employing nuclear magnetic resonance (NMR) spectroscopy to verify the identity and purity of compounds. This serves as a critical aspect in ensuring the integrity and reliability of research data. To this end, Dr. Nagumalli conducts qualitative and quantitative analyses of compounds used in research utilizing an advanced NMR system.

Additionally, Dr. Nagumalli is pioneering the analysis of the toxicity of mixtures. This involves applying a blend of NMR and mass spectrometry techniques alongside multivariate data analysis methods, including PCA, hierarchical clustering analysis, and partial least squares regression. This approach allows for the identification of hazards related to complex chemical mixture exposure, thereby enhancing the field of mixture toxicity analysis and supporting informed decision-making.

Dr. Nagumalli has acquired substantial expertise in analytical chemistry and advanced multivariate data analysis using the R programming language. His unique position at the crossroads of toxicology, analytical chemistry, and data science enables him to explore the complex interactions between chemicals and biological systems. This interdisciplinary skill set is instrumental in advancing pharmacological and toxicological evaluations, contributing to better public health outcomes.

 

Professional Societies/National and International Groups

American Chemical Society
Member
2017 – Present

American Society of Mass Spectrometry
Member
2018 – Present

Metabolomics Association of North America
Member
2019 – Present

Phi Kappa Phi Honor Society (ULM chapter)
Member
2015 – Present

Sigma Xi 
Member
2018 – Present

Society of Toxicology
Member
2015 – Present

 

Selected Publications

Assessment of Clinical Chemistry and Hematological Parameters in Female Sprague-Dawley Rats Following a 7-Day Oral Exposure to Three Different Species of Echinacea.
Nagumalli S.K., Salley J.T., and Carstens J.D.
Journal of Environmental Science and Health, Part C. 2024, 1-18.

1H-NMR-Based Chemometric Analysis of Echinacea Species to Predict Effectors of Myeloid Progenitor Stimulation.
Nagumalli S.K., Salley J.T., and Carstens J.D.
Analytica. 2024, 5(1): 28-53.

Effect of an Obesogenic High-Fat and High-Sucrose Diet on Hepatic Gene Expression Signatures in Male Collaborative Cross Mice.
Tryndyak V.P., Willett R.A., Nagumalli S.K., Li D., Avigan M.I., Beland F.A., Rusyn I., and Pogribny I.P.
American Journal of Physiology-Gastrointestinal and Liver Physiology. 2023, 324(3): G232-G243.

Lipidomic Profiling of the Hepatic Esterified Fatty Acid Composition in Diet-Induced Nonalcoholic Fatty Liver Disease in Genetically Diverse Collaborative Cross Mice.
Nagumalli S.K., Willett R.A., de Conti A., Tryndyak V.P., Avigan M.I., da Costa G.G., Beland F.A., Rusyn I., and Pogribny I.P.
The Journal of Nutritional Biochemistry. 2022, 109: 109108.

A Rapid and Highly Sensitive UPLC-ESI-MS/MS Method for the Analysis of the Fatty Acid Profile of Edible Vegetable Oils.
Nagumalli S.K., Jacob C.C., and da Costa G.G.
Journal of Chromatography B. 2020, 1161: 122415.

(−)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo.
Siddique A.B., Ebrahim H.Y., Akl M.R., Ayoub N.M., Goda A.A., Mohyeldin M.M., Nagumalli S.K., Hananeh W.M., Liu Y., Meyer S.A., and El Sayed K.A.
Nutrients. 2019, 11(2): 412.

Contact Information
Suresh K. Nagumalli
(870) 543-7121
Expertise
Expertise
Approach
Domain
Technology & Discipline
Toxicology
Back to Top